X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. Akston is continuing its progress to secure Emergency Use Authorization (EUA) in India and has begun working with a new CDMO to produce AKS-452.
Lead Product(s): AKS-452
Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Akston Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination March 07, 2023
Details:
Sputnik Light (rAd26) vaccine demonstrates 91.6% efficacy rate against coronavirus, the world’s first registered vaccine against the novel coronavirus infection, is now approved for use in over 50 countries.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Russian Direct Investment Fund
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
